Browsing Tag
Novartis
97 posts
Novartis drops ALS drug lifonebart after Phase 2 trial misses key goals
Novartis has discontinued development of VHB937, or lifonebart, in amyotrophic lateral sclerosis after a 251-patient Phase 2 trial missed its primary and secondary objectives, adding to several recent pipeline disappointments.
Legend Biotech names Ingrid Zhang CEO as CARVYKTI sales surge 50%
Legend Biotech Corporation has appointed former Novartis commercial executive Ingrid Zhang as chief executive after a seven-week leadership search, putting an experienced global medicines operator in charge as CARVYKTI sales accelerate and the cell therapy company tries to build its next growth engine.
Novartis and Ionis suffer pelacarsen setback as 8,000-patient heart trial misses endpoint
Novartis and Ionis Pharmaceuticals have suffered a major Phase III setback after pelacarsen successfully lowered lipoprotein(a) but failed to reduce cardiovascular events, challenging one of the most closely watched hypotheses in heart-drug development.
Novartis pelacarsen fails 8,323-patient Phase III test despite lowering Lp(a)
Novartis’ pelacarsen has failed the primary endpoint in the 8,323-patient Phase III Lp(a)HORIZON trial despite lowering lipoprotein(a), delivering a major setback to one of cardiovascular medicine’s most closely watched drug-development hypotheses and raising new questions for competing Lp(a)-lowering programmes.
Novartis gains another potential MS growth engine after remibrutinib beats teriflunomide in two Phase III trials
Novartis shares surge after remibrutinib wins two Phase III MS trials, opening another potential growth opportunity alongside Kesimpta.
Novartis wins FDA nod for Pluvicto in hormone-sensitive prostate cancer, nearly doubling its addressable pool
FDA's mHSPC label nod nearly doubles Pluvicto's addressable pool. Novartis' five RLT plants and payer coverage now decide how fast $651M Q2 sales scale.
Nuvectis Pharma’s ciprocopan approval validates its Haisco deal but raises the execution stakes
Nuvectis Pharma gains ciprocopan validation in China, but licensing costs, dilution and ex-China execution will determine its real value.
Nuvectis Pharma just raised $100 million, so why are NVCT shareholders selling?
Nuvectis Pharma shares fell 19% after a $100 million offering priced at $20. Read what dilution, runway and pipeline expansion mean for NVCT investors now!
Why Grasim chose Pantaloons veteran Sangeeta Tanwani to lead its textiles business
Sangeeta Tanwani’s move from consumer retail to Grasim Industries’ textiles business signals a stronger push toward branded fabrics, premium products and customer-led growth.
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.